Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Paolo Nuciforo, John Townend, Martine J Piccart, Shona Fielding, Panagiota Gkolfi, Sarra El-Abed, Evandro de Azambuja, Gustavo Werutsky, Judith Bliss, Volker Moebus, Marco Colleoni, Alvaro Moreno Aspitia, Henry Gomez, Andrea Gombos, Maria A Coccia-Portugal, Ling-Ming Tseng, Georg Kunz, Guillermo Lerzo, Joohyuk Sohn, Vladimir Semiglazov, Cristina Saura, Judith Kroep, Antonella Ferro, David Cameron, Richard Gelber, Jens Huober, Serena Di Cosimo
Eur J Cancer 181 92-101
摘要
摘要
BACKGROUND: Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR. METHODS: Neoadjuvant lapatinib and/or trastuzumab treatment optimisation (NCT00553358) is an international, randomised, open-label, phase III study investigating the addition of lapatinib to chemotherapy plus trastuzumab in HER2-positive early BC. Ten-year event-free survival (EFS), overall survival (OS) and safety were assessed on intention-to-treat population. The association between pCR and EFS or OS was investigated in landmark population. RESULTS: A total of 455 patients were randomised to receive lapatinib (154), trastuzumab (149) or the combination (152). Ten-year EFS estimates were 63% (95% confidence interval [CI], 54%-71%) in the lapatinib group, 64% (95% CI, 55%-72%) in the trastuzumab group and 67% (95% CI, 58%-74%) in the combination group. Ten-year OS rates were 76% (95% CI, 67%-83%), 75% (95% CI, 66%-82%) and 80% (95% CI, 73%-86%) in the lapatinib, trastuzumab and combination groups, respectively. Women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31-0.73) and OS (hazard ratio 0.37, 95% CI, 0.20-0.63) compared with those who did not. The numerical difference in survival according to pCR status was greater in women treated with the combination and those with hormone-receptor-negative tumours. There were no new or long-term safety concerns. CONCLUSIONS: Patients with HER2-positive BC showed a durable survival benefit of neoadjuvant anti-HER2, irrespective of treatment arm. Patients who achieve pCR have significantly better outcomes than patients without pCR.
KM 提取结果
0 个 Figure · 0 个 KM 面板